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Dihydropyrimidinones are an important class of compounds
due to their therapeutic and pharmacological properties, such
as anti-inﬂammatory (Sadanandam et al., 1992), antihyperten-
sion (Chikhale et al., 2009), anticancer (Kumar et al., 2009) and9448824075; fax: +91 824
m (B. Kalluraya).
y. Production and hosting by
Saud University.
lsevierantimicrobial (Chitra et al., 2010) activities. They also act as
inhibitors for the propagation of the malarial parasite (Chiang
et al., 2009), calcium channel blocking agents (Manjula et al.,
2004; Singh et al., 2009), inhibitor of rho kinase (ROCK1)
(Sehon et al., 2008), inhibitor of human kinesin (Eg5) (Kaan
et al., 2010) and as anti-HBV agents (Zhu et al., 2010).
The common synthetic routes to these compounds generally
involve multi-step transformations that are essentially based on
the Biginelli condensation methodology. Multicomponent
reactions constitute major importance in organic synthesis be-
cause of its diversity, efﬁciency and quick access to highly func-
tionalized organic molecules which make them signiﬁcant in
drug discovery process (Sujith et al., 2009; Isloor et al., 2009).
Prompted by these observations and in continuation of our
search for green technique (Hegde et al., 2007; Priya et al., 2007;
Rai et al., 2009; Gowda et al., 2010) we herein report the syn-
thesis of title compounds using microwave (MW) energy. Re-
cently a major development that had a profound impact on
heterogeneous reactions is the use of MW irradiation
76 A. Adhikari et al.techniques. This approach has been used for a variety of appli-
cations in organic synthesis and functional group transforma-
tions. MW assisted heating under controlled conditions is an
invaluable technology because it often dramatically reduces
reactions times, typically from days or hours to minutes or even
seconds (Larhed and Hallberg, 2001; Lidstro¨m et al., 2001).
2. Experimental
2.1. General
Purity of the newly synthesized compounds was checked by
TLC on silica gel plates (Merck, Silica gel 60F254). Melting
points were determined in open capillary tubes and are uncor-
rected. Elemental analysis was carried out in Vario EL III
Elementa model. IR spectra were recorded by dispersing the
compounds in KBr pellets on a Schimadzu FT-IR 157 spectro-
photometer. 1H NMR spectra were recorded on a Bruker
Avance II 400 MHz NMR spectrometer and all the chemical
shift values were reported as d (ppm). 13C NMR spectra were
recorded on a Bruker Avance II 400 MHz NMR spectrometer.
Mass spectra were recorded on a JEOL JMS – D300 mass spec-
trometer operating at 70 eV. Microwave reactions were carried
out in Godrej (GMC 20E 08 SSGX) microwave oven. Title
compounds are prepared as shown in Scheme 1. The precursor
6-substituted-2-chloro-3-formylquinoline (1) was prepared
from substituted acetanilides (Meth-Cohn et al., 1981).
2.2. General method for the preparation of 6-substituted-2-
hydroxyquinoline-3-carbaldehyde (2a–c)
We modiﬁed our earlier procedure (Kalluraya et al., 2003) for
the synthesis of compounds 2a–c. In this method in a 250 mLN OH
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Schemebeaker, 6-substituted-2-chloro-3-formylquinolines (1)
(0.01 mol) was taken along with a solution of HCl (35 mL,
4 M) and subjected to MW irradiation (120 W) for 6 min. As
the beaker was allowed to cool, yellow solid precipitates out.
This was poured into a beaker containing crushed ice
(100 g), ﬁltered, dried and recrystallised from acetic acid.
2.3. General method for the preparation of 1-substituted-4-(6-
substituted-2-hydroxyquinoline-3-yl)-5-acetyl/carboxyethyl-6-
methyl-pyrimidine-2-one/thiones (3a–l)
2.3.1. Conventional method
In a 50 mL R.B. ﬂask 6-substituted-2-hydroxyquinoline-
3-carbaldehyde (0.01 mol), ethylacetoacetate/acetylacetone
(0.012 mol), urea/thiourea/phenylthiourea (0.01 mol) and
DMF (10 mL) were taken. Added two drops of conc. H2SO4
and reﬂuxed on an oil bath. Completion of the reaction was
monitored by TLC. The solid precipitated was ﬁltered, washed
with ethanol, dried and recrystallised using DMF.
2.3.2. Microwave method
6-Substituted-2-hydroxyquinoline-3-carbaldehyde (0.005 mol),
ethylacetoacetate/acetylacetone (0.005 mol), urea/thiourea/
phenylthiourea (0.005 mol) and DMF (5 mL) were taken in a
100 mL beaker. Added two drops of conc. H2SO4 and sub-
jected to MW irradiation (160 W). The completion of the reac-
tion was monitored using TLC. The solid precipitated was
ﬁltered, washed with ethanol, dried and recrystallised using
DMF. M.P., time required and yield data of the newly synthe-
sized compounds are summarized in Table 1.
2.3.2.1. 4–(2-Hydroxyquinoline-3-yl)-5-carboxyethyl-6-
methyl–pyrimidine-2-one (3a). IR (KBr) c/cm1: 3106.7 (O–
H), 2982.1 (C–H), 1705.8 (ester C‚O), 1664.5 (amideN OH
N
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Table 1 Physical data of 1-substituted-4-(6-substituted-2-hydroxyquinoline-3-yl)-5-acetyl/carboxyethyl-6-methyl-pyrimidine-2-one/
thiones (3a–l).
Compound Time Yield % Melting point (C)
Conventional (h) MW (min) Conventional MW
3a 6 5 63 71 285
3b 8 4.5 60 78 283
3c 5 5 65 82 286
3d 6 4.5 59 69 278
3e 7 4.5 62 71 281
3f 6 5 63 78 297
3g 7 5 67 81 293
3h 5 5 65 79 279
3i 7 4 66 82 291
3j 8 4.5 61 74 285
3k 7 5 50 69 277
3l 6 5 61 69 283
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CH3), 3.95 (q, 2H, CH2), 5.32 (d, 1H, CH), 7.09–7.68 (m, 5H,
Ar-H), 7.7 (s, 1H, NH), 9.21 (s, 1H, N–H), 11.87 (s, 1H, OH);
MS: m/z= 328 [M++1], Anal. calcd for C17H17N3O4 (%): C,
62.38; H, 5.23; N, 12.84. Found: C, 62.25; H, 5.18; N, 12.58.
2.3.2.2. 1-Phenyl-4-(2-hydroxyquinoline-3-yl)-5-carboxyethyl-
6-methyl–pyrimidine-2-thione (3b). IR (KBr) c/cm1: 3169.7
(O–H), 2976.6 (C–H), 1715.5 (ester C‚O), 1664.8 (amide
C‚O); 1H NMR (DMSO-d6) d: 1.03 (t, 3H, CH3), 2.3 (s,
3H, CH3), 3.89 (q, 2H, CH2), 5.33 (d, 1H, CH), 7.0–7.71 (m,
10H, Ar-H), 8.95 (s, 1H, N–H), 11.98 (s, 1H, OH); MS:
m/z= 420 [M++1], Anal. calcd for C23H21N3O3S (%): C,
65.85; H, 5.05; N, 10.02. Found: C, 65.75; H, 4.98; N, 9.98.
2.3.2.3. 4–(2-Hydroxyquinoline-3-yl)-5-carboxyethyl-6-
methyl–pyrimidine-2-thione (3c). IR (KBr) c/cm1: 3145.8
(O–H), 2952.3 (C–H), 1721.9 (ester C‚O), 1631.5 (amide
C‚O); 1H NMR (DMSO-d6) d: 1.05 (t, 3H, CH3), 2.31 (s,
3H, CH3), 3.73 (q, 2H, CH2), 5.40 (d, 1H, CH), 7.03–7.8 (m,
5H, Ar-H), 8.5 (s, 1H, N–H), 9.01 (s, 1H, N–H), 12.02 (s,
1H, OH); MS: m/z= 344 [M++1], Anal. calcd for
C17H17N3O3S (%): C, 59.46; H, 4.99; N, 12.24. Found: C,
59.37; H, 4.98; N, 12.18.
2.3.2.4. 4–(6-Methyl-2-hydroxyquinoline-3-yl)-5-carboxyethyl-
6-methyl–pyrimidine-2-one (3d). IR (KBr) c/cm1: 3211.4 (O–
H), 2960.7 (C–H), 1703.5 (ester C‚O), 1625.1 (amide C‚O);
1H NMR (DMSO-d6) d: 1.05 (t, 3H, CH3), 2.31 (s, 3H, CH3),
2.33 (s, 3H, CH3), 3.97 (q, 2H, CH2), 5.34 (d, 1H, CH), 7.07–
7.49 (m, 4H, Ar-H), 7.5 (s, 1H, NH), 9.2 (s, 1H, N–H), 11.81
(s, 1H, OH); MS: m/z= 342 [M++1], Anal. calcd for
C18H19N3O4 (%): C, 63.33; H, 5.61; N, 12.31. Found: C,
63.26; H, 5.56; N, 12.23; 13C NMR (DMSO-d6) d: 14.13,
17.85, 20.32, 49.45, 59.05, 96.06, 114.69, 118.8, 127.62,
130.84, 131.35, 133.33, 134.47, 136.1, 150.12, 152.12, 161.11,
165.17.
2.3.2.5. 1-Phenyl-4–(6-methyl-2-hydroxyquinoline-3-yl)-5-
carboxyethyl-6-methyl–pyrimidine-2-thione (3e). IR (KBr)
c/cm1: 3159.5 (O–H), 2969.5 (C–H), 1719.1 (ester C‚O),
1649.9 (amide C‚O); 1H NMR (DMSO-d6) d: 1.38 (t, 3H,
CH3), 2.43 (s, 3H, CH3), 3.33 (s, 3H, CH3), 4.38 (q, 2H,
CH2), 5.35 (d, 1H, CH), 7.1–7.59 (m, 9H, Ar-H), 8.43(s, 1H, N–H), 11.91 (s, 1H, OH); MS: m/z= 434 [M++1],
Anal. calcd for C24H23N3O3S (%): C, 66.49; H, 5.35; N,
9.69. Found: C, 66.46; H, 5.26; N, 9.57.
2.3.2.6. 4–(6-Methyl-2-hydroxyquinoline-3-yl)-5-carboxyethyl-
6-methyl–pyrimidine-2-thione (3f). IR (KBr) c/cm1: 3235.6
(O–H), 2969.4 (C–H), 1710.4 (ester C‚O), 1628.2 (amide
C‚O); 1H NMR (DMSO-d6) d: 1.13 (t, 3H, CH3), 2.39 (s,
3H, CH3), 3.31 (s, 3H, CH3), 4.21 (q, 2H, CH2), 5.37 (d, 1H,
CH), 7.1–7.68 (m, 4H, Ar-H), 8.37 (s, 1H, N–H), 8.9 (s, 1H,
N–H), 11.93 (s, 1H, OH); MS: m/z= 358 [M++1], Anal.
calcd for C18H19N3O3S (%): C, 60.49; H, 5.36; N, 11.76.
Found: C, 60.37; H, 5.28; N, 11.68.
2.3.2.7. 4–(6-Methyl-2-hydroxyquinoline-3-yl)-5-acetyl-6-
methyl–pyrimidine-2-one (3g). IR (KBr) c/cm1: 3210.1 (O–
H), 2899.6 (C–H), 1688.6 (acetyl C‚O), 1634.5 (amide
C‚O); 1H NMR (DMSO-d6) d: 2.14 (s, 3H, CH3), 2.31 (s,
3H, CH3), 3.34 (s, 3H, CH3), 5.41 (d, 1H, CH), 7.07–7.48
(m, 5H, Ar-H), 9.2 (s, 1H, N–H), 11.9 (s, 1H, OH); MS:
m/z= 312 [M++1], Anal. calcd for C17H17N3O3 (%): C,
65.58; H, 5.50; N, 13.5. Found: C, 65.47; H, 5.38; N, 13.41.
2.3.2.8. 1-Phenyl-4-(2-hydroxyquinoline-3-yl)-5-acetyl-6-
methyl–pyrimidine-2-thione (3h). IR (KBr) c/cm1: 3227.5
(O–H), 2899.6 (C–H), 1694.7 (acetyl C‚O), 1652.5 (amide
C‚O); 1H NMR (DMSO-d6) d: 2.14 (s, 3H, CH3), 3.34 (s,
3H, CH3), 5.38 (d, 1H, CH), 6.9–7.9 (m, 10H, Ar-H), 8.28
(s, 1H, N–H), 12.06 (s, 1H, OH); MS: m/z= 374 [M++1],
Anal. calcd for C22H19N3O2S (%): C, 67.84; H, 4.92; N,
10.79. Found: C, 67.76; H, 4.88; N, 10.71.
2.3.2.9. 4–(2-Hydroxyquinoline-3-yl)-5-acetyl-6-methyl–pyrim-
idine-2-thione (3i). IR (KBr) c/cm1: 3169.3 (O–H), 2973.5
(C–H), 1689.1 (acetyl C‚O), 1627.3 (amide C‚O); 1H
NMR (DMSO-d6) d: 2.16 (s, 3H, CH3), 3.31 (s, 3H, CH3),
5.43 (d, 1H, CH), 7.1–7.8 (m, 5H, Ar-H), 8.31 (s, 1H, N–H),
8.92 (s, 1H, N–H), 11.98 (s, 1H, OH); MS: m/z= 314
[M++1], Anal. calcd for C16H15N3O2S (%): C, 61.32; H,
4.82; N, 13.41. Found: C, 61.27; H, 4.78; N, 13.28.
2.3.2.10. 4–(2-Hydroxyquinoline-3-yl)-5-acetyl-6-methyl–
pyrimidine-2-one (3j). IR (KBr) c/cm1: 3128.8 (O–H),
2945.9 (C–H), 1684.7 (acetyl C‚O), 1635.7 (amide C‚O);
78 A. Adhikari et al.1H NMR (DMSO-d6) d: 2.18 (s, 3H, CH3), 3.34 (s, 3H, CH3),
5.37 (d, 1H, CH), 7.1–7.79 (m, 5H, Ar-H), 8.29 (s, 1H, N–H),
8.89 (s, 1H, N–H), 12.02 (s, 1H, OH); MS: m/z= 298
[M++1], Anal. calcd for C16H15N3O3 (%): C, 64.64; H,
5.09; N, 14.13. Found: C, 64.57; H, 5.01; N, 14.08.
2.3.2.11. 4–(6-Methyl-2-hydroxyquinoline-3-yl)-5-acetyl-6-
methyl–pyrimidine-2-thione (3k). IR (KBr) c/cm1: 3224.7
(O–H), 2904.8 (C–H), 1685.9 (acetyl C‚O), 1638.8 (amide
C‚O); 1H NMR (DMSO-d6) d: 2.15 (s, 3H, CH3), 2.33 (s,
3H, CH3), 3.34 (s, 3H, CH3), 5.44 (d, 1H, CH), 7.03–7.62
(m, 5H, Ar-H), 8.92 (s, 1H, N–H), 11.97 (s, 1H, OH); MS:
m/z= 328 [M++1], Anal. calcd for C17H17N3O2S (%): C,
62.36; H, 5.23; N, 12.83. Found: C, 62.27; H, 5.18; N, 12.71.
2.3.2.12. 1-Phenyl-4-(6-methyl-2-hydroxyquinoline-3-yl)-5-
acetyl-6-methyl–pyrimidine-2-thione (3l). IR (KBr) c/cm1:
3235.1 (O–H), 2926.5 (C–H), 1684.8 (acetyl C‚O), 1642.2
(amide C‚O); 1H NMR (DMSO-d6) d: 2.15 (s, 3H, CH3),
2.34 (s, 3H, CH3), 3.35 (s, 3H, CH3), 5.43d, 1H, CH), 7.1–
7.9 (m, 9H, Ar-H), 8.51 (s, 1H, N–H), 11.95 (s, 1H, OH);
MS: m/z= 404 [M++1], Anal. calcd for C23H21N3O2S (%):
C, 68.46; H, 5.25; N, 10.41. Found: C, 68.39; H, 5.18; N, 10.31.
3. Results and discussion
3.1. Chemistry
Our modiﬁed method describes the successful conversion of
6-substituted-2-chloro-3-formylquinolines (1) into 6-substi-
tuted-2-hydroxyquinoline-3-carbaldehyde (2) under MW irra-
diation. This method is rapid and convenient over
conventional heating method. Also when these (2) wereTable 2 DPPH radical scavenging activity of compounds 3a–l.
Compound no. 3a 3b 3c 3d 3e 3f
% Inhibition 83.27 86.61 81.71 85.33 89.54 80.14
Table 3 Antibacterial data of compounds 3a–l.
Compound Zone of inhibition in mm
E. coli P. aeru
100 lg/mL 50 lg/mL 100 lg
3a 17 12 16
3b 16 11 14
3c 20 18 18
3d 21 17 17
3e 17 13 15
3f 18 14 16
3g 17 12 17
3h 15 10 17
3i 20 17 19
3j 17 14 16
3k 18 16 15
3l 15 12 18
Standard 19 15 18
Control 0 0 0subjected to MW irradiation along with substituted urea/thio-
urea and active methylene compound underwent rapid
Biginelli reaction to afford 1-substituted-4-(6-substituted-2-
hydroxyquinoline-3-yl)-5-acetyl/ carboxyethyl-6-methyl-
pyrimidine-2-one/thiones (3) than conventional heating
method. These reactions are summarized in Scheme 1 and
results are presented in Table 1.
3.2. DPPH radical scavenging activity
Literature procedure (Williams et al., 1995) was followed for
evaluation of the free radical-scavenging capacity. Brieﬂy,
1 mL of the test sample (100 lg/mL) was mixed with the meth-
anolic 2,2-diphenyl-1-picrylhydrazyl (DPPH) solution (2 mL,
0.2 mM). The absorbance was measured at 517 nm immedi-
ately after standing at room temperature for 30 min. The per-
centage of scavenging has been calculated as the ratio of the
absorption of the sample relative to the control DPPH
(0.2 mM) solution without test samples. DPPH radical-scav-
enging activity was expressed as the inhibition percentage. Re-
sults are shown in Table 2.
3.3. Antibacterial activity
The bacteria namelyEscherichia coli,Staphylococcus aureus and
Pseudomonas aeruginosa were screened for their sensitivity to-
wards synthesized compounds by Agar well diffusion method
(Tepe et al., 2004). In thismethod, 24 holdMuller–Hinton broth
cultures of test bacteria were swabbed uniformly on solidiﬁed
sterile Muller–Hinton agar plates using sterile cotton swab.
Then, aseptically wells of 6 mmdiameter were bored in the inoc-
ulated plates with the help of gel puncher and the samples
(100 lL; 10 mg/mL of DMSO), standard (Chloramphenicol,3g 3h 3i 3j 3k 3l BHT
81.11 89.10 81.23 82.89 82.61 81.30 91.64
ginosa S. aureus
/mL 50 lg/mL 100 lg/mL 50 lg/mL
10 14 10
11 13 11
14 16 14
13 16 12
10 15 12
13 16 11
15 15 10
13 16 11
12 16 12
14 15 11
14 16 14
14 15 13
13 16 11
0 0 0
Table 4 Antifungal data of compounds 3a–l.
Compound Zone of inhibition in mm at 100 mg/mL
C. albicans A. ﬂavus
3a 15 18
3b 17 18
3c 17 15
3d 19 18
3e 16 17
3f 12 14
3g 13 15
3h 20 18
3i 18 20
3j 17 16
3k 14 15
3l 16 18
Standard 20 21
Control 0 0
Synthesis, characterization and biological evaluation of dihydropyrimidine derivatives 791 mg/mL) and control (DMSO)were added into the respectively
labeled wells. The plates were incubated at 37 C for 24 h in up-
right position and the zone of inhibition was recorded. Among
the compounds tested 3c, 3d and 3i showed good activity. The
results are presented in Table 3.
3.4. Antifungal activity
Synthesized compounds were screened for antifungal activity
by agar well diffusion method (Perez et al., 1990) with sterile
cork borer of size 6.0 mm. The cultures of 48 h old grown on
potato dextrose agar (PDA) were used for inoculation of fun-
gal strain on PDA plates. An aliquot (0.02 ml) of inoculum
was introduced to molten PDA and poured into a petri dish.
After solidiﬁcation, the appropriate wells were made on agar
plate by using cork borer. Incubation period of 24–48 h at
28 C was maintained for observation of antifungal activity
of the compounds. The antifungal activity was evaluated by
measuring zones of inhibition of fungal growth. The complete
antifungal analysis was carried out under strict aseptic condi-
tions. The zones of inhibition were measured. Among the com-
pounds tested 3c, 3d, 3h and 3i showed signiﬁcant activity. All
the results are shown in Table 4.
4. Conclusion
Synthesis of heterocyclic compounds like pyrimidines bearing
quinoline moiety generally involves prolonged heating condi-
tion. Therefore, researchers continue to discover simple, rapid
and convenient routes for the synthesis of these heterocycles.
Therefore, on the basis of the results obtained it can be con-
cluded that our approach to the synthesis of dihydropyrimi-
dines bearing quinoline moiety using MW assistance is rapid
and useful over conventional heating technique. In short a
convenient and high-yielding methodology to synthesize
pyrimidines bearing quinoline moiety has been developed.
Furthermore the results obtained from antioxidant, anti-
fungal and antibacterial screening of the novel compounds
are encouraging. Most of the compounds tested showed mod-
erate to good pharmacological activities when compared tostandard. Thus on the basis of the results obtained it can be
concluded that the dihydropyrimidines bearing quinoline moi-
ety demonstrated good antioxidant, antibacterial and anti-
fungal activities.Acknowledgement
The author A.A. thanks University Grant Commission for the
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